Please login to the form below

Not currently logged in
Email:
Password:

Icon appoints Allergan’s Ira Spector

He also has 17 years’ experience at Wyeth
icon ira spector

Dr Ira Spector has left his senior role at Allergan to join the clinical research organisation (CRO) Icon as executive VP, analytics and consulting.

Dr Spector was most recently senior VP of global development operations at Allergan where he spent four years. Prior to this he spent 17 years at Wyeth, leaving shortly after the company's takeover by Pfizer.

In his new role at Icon Dr Spector will lead the company's global consulting and drug development services and will also be responsible for Icon's business process improvement and analytics capabilities.

Icon's chief operating officer Dr Steve Cutler commented on the new appointment: “His extensive experience in managing some of the world's largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers' drug and device programmes.”

10th September 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...